Ângela Fernandes

A team from the Institute for Research and Innovation in Health at the University of Porto (i3S), led by Salomé Pinho, has discovered a new strategy to make (CAR-)T cell therapies more effective against solid tumors. The findings were published in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR).

Uma equipa do Instituto de Investigação e Inovação em Saúde da Universidade do Porto (i3S), liderada por Salomé Pinho, descobriu uma nova estratégia de tornar as terapias com células T (CAR-T) mais eficazes contra tumores sólidos. Os resultados foram publicados na revista Cancer Immunology Research, da American Association for Cancer Research(AACR).

A recent study, led by Ricardo Marcos-Pinto and Ângela Fernandes, with Henrique Fernandes-Mendes as its first author, revealed associations between aberrant glycoprofiles and clinical variables. This study, conducted in the Immunology, Cancer & Glycomedicine group at i3S (led by Salomé Pinho), reveals an association between the levels of branched N-glycans in epithelial cells and factors such as age, smoking and polyp dimension, suggesting a link between these glycans and colorectal cancer progression.

Um estudo recente, liderado pelos investigadores Ricardo Marcos-Pinto e Ângela Fernandes, com a primeira autoria de Henrique Fernandes-Mendes, revelou associações entre perfis de glicosilação aberrantes e diversas variáveis clínicas.